Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals Inc. Chief Executive Officer and director Brett P. Monia reported selling 29,430 shares of common stock on February 6, 2026 at a weighted average price of $85.7907 per share. The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on August 13, 2024. Following this transaction, Monia beneficially owned 254,497 shares of Ionis common stock in direct form.
IONS filer Brett Monia submitted a Rule 144 notice for the proposed sale of 290,203 shares of common stock through Stifel Nicolaus & Company Inc. on or about 02/06/2026 on Nasdaq, with an aggregate market value of 24826867.00.
The shares to be sold were acquired on 01/15/2026 as restricted stock units from the issuer as equity compensation. The notice states that 161,974,393 shares of this class were outstanding. During the prior three months, Monia sold 44,034 and 62,970 shares of common stock for gross proceeds of 3357167.00 and 5223749.00, respectively.
Ionis Pharmaceuticals executive C. Frank Bennett reported option exercises and stock sales. As EVP and Chief Scientific Officer, he exercised non-qualified stock options for 48,626 shares at $60.89 and 16,463 shares at $32.6, then converted them into common stock.
On the same date, he sold 20,000 shares at a weighted-average price of $82.599 and sold 48,626 and 16,463 shares at a weighted-average price of $83.0284, in multiple trades within disclosed price ranges. After these transactions, he directly owned 80,293 common shares and 2,406 option shares.
Ionis Pharmaceuticals executive Eric Swayze reported equity transactions in company stock. On January 29, 2026, he acquired 11,991 shares of common stock at $0.0 per share from the vesting of performance-based restricted stock units, after the Compensation Committee certified achievement of the relative total shareholder return goal at 167.27% of target shares.
On January 30, 2026, he sold 6,179 shares of Ionis common stock at a weighted average price of $82.9335 per share, in multiple transactions within a narrow price range. Following these transactions, he directly beneficially owned 47,747 shares, and an additional 318 shares were held indirectly by his son.
Ionis Pharmaceuticals executive Eugene Schneider reported two stock transactions. On January 29, 2026, he acquired 11,991 shares of common stock at $0.00 when performance-based restricted stock units vested. The Compensation Committee certified performance at 167.27% of target shares based on relative total shareholder return.
On January 30, 2026, Schneider sold 6,179 shares of common stock at a weighted average price of $83.4487, in multiple trades between $83.32 and $83.48. After these transactions, he directly owned 69,702 shares of Ionis common stock.
Ionis Pharmaceuticals EVP, CLO & General Counsel Patrick R. O'Neil reported an equity award vesting and a share sale. On 01/29/2026 he acquired 11,991 shares of common stock at $0.0 upon vesting of performance-based RSUs, after the Compensation Committee certified performance at 167.27% of target shares. On 01/30/2026 he sold 6,179 common shares at a weighted average price of $83.5335 per share in multiple trades between $83.48 and $83.67. Following these transactions, he directly owned 71,983 Ionis common shares.
Ionis Pharmaceuticals CEO Brett P. Monia reported two stock transactions. On January 29, 2026, he acquired 122,214 shares of common stock at $0.00 upon vesting of performance-based restricted stock units. These PRSUs vested at 167.27% of target, based on Ionis’s relative total shareholder return versus a peer group.
On January 30, 2026, Monia sold 62,970 shares of Ionis common stock at a weighted average price of $82.7216, from multiple trades between $82.26 and $82.925. After these transactions he directly owned 283,927 shares of Ionis common stock.
Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported two stock transactions. On January 29, 2026, she acquired 13,562 shares of common stock at $0.00 per share from the vesting of performance-based restricted stock units tied to relative total shareholder return, which vested at 167.27% of target shares. On January 30, 2026, she sold 6,988 shares of common stock at a weighted average price of $83.243 per share, with individual sale prices ranging from $83.11 to $83.32. Following these transactions, she directly owned 132,881 shares of Ionis Pharmaceuticals common stock.
Ionis Pharmaceuticals executive Brian Birchler reported an equity award and a share sale. On 01/29/2026, he acquired 11,991 shares of common stock at $0.0 per share upon vesting of performance-based restricted stock units tied to relative total shareholder return, which vested at 167.27% of target.
On 01/30/2026, Birchler sold 6,179 common shares at a weighted average price of $83.0309, in multiple trades between $83.00 and $83.08. After these transactions, he directly owned 66,247 Ionis shares as EVP, Corp and Development Ops.
Ionis Pharmaceuticals executive C. Frank Bennett reported a mix of equity vesting and share sales. On January 29, 2026, he acquired 11,421 shares of common stock at $0.0 upon vesting of performance-based restricted stock units. The Compensation Committee certified performance at 167.27% of target shares based on relative total shareholder return versus a peer group, within a possible payout range of 0% to 200%.
On January 30, 2026, Bennett sold 5,885 shares of common stock at a weighted average price of $82.9466, from multiple trades between $82.94 and $82.95. After these transactions, he directly owned 100,293 shares of Ionis common stock.